Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer
Our study indicates that patients emerge from T-DXd treatment with highly refractory disease. These findings highlight the urgent need for optimized treatment strategies and novel therapeutic options for this patient population.
Authors
- Joshua Z. Drago (ORCID: https://orcid.org/0000-0002-7245-1172)
- Shanu Modi (ORCID: https://orcid.org/0000-0001-6427-7373)
- Sarat Chandarlapaty (ORCID: https://orcid.org/0000-0003-4532-8053)
- Grace Gallagher (ORCID: https://orcid.org/0009-0004-9277-5002)
- Mithat Gönen (ORCID: https://orcid.org/0000-0001-8683-8477)
- Chau T. Dang (ORCID: https://orcid.org/0000-0001-5133-2265)
- Sophia Zelizer
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Princeton University (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1007/s10549-025-07853-w
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00